Latest news with #bcic.bio.org
Yahoo
05-02-2025
- Business
- Yahoo
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics'), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O'Heeron, Chief Executive Officer Hamid Khoja, PhD, Chief Scientific Officer Robert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiologics' research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases. A live Q&A session will follow the formal presentations. An audio recording of the presentation and Q&A will be available under the investor section of the FibroBiologics website after the event. In addition, FibroBiologics will be presenting at the 2025 BIO CEO & Investor Conference in New York, NY, from February 10-11. Details of the event are as follows: Date: Tuesday, February 11Time: 11:15 a.m. ETLocation: The New York Marriott MarquisTrack: Plymouth Room To learn more about the event, please visit or to schedule one-on-one meetings, please email FibroBiologicsIR@ About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit General Inquiries:info@ Investor Relations:Nic Johnson Russo Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347)
Yahoo
05-02-2025
- Business
- Yahoo
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ('Lisata' or the 'Company'), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate overview at the 2025 BIO CEO & Investor Conference taking place February 10-11, 2025 at the New York Marriott Marquis in New York City. Dr. Mazzo's presentation is scheduled for Monday, February 10th at 2:00 p.m. Eastern Time. For more information about the conference and how to register, please visit About Lisata Therapeutics Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next 1.5 years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. Learn more about certepetide's mechanism of action in our short film. For more information on the Company, please visit Contact: Investors:Lisata TherapeuticsJohn MendittoVice President, Investor Relations and Corporate CommunicationsPhone: 908-842-0084Email: jmenditto@ Media:ICR HealthcareElizabeth ColemanAccount SupervisorPhone: 203-682-4783Email: This press release was published by a CLEAR® Verified in to access your portfolio
